Internalization, Intracellular Trafficking, and Biodistribution of Monoclonal Antibody 806: A Novel Anti-Epidermal Growth Factor Receptor Antibody

Documenti analoghi

• Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478
  di: Johns, Terrance G., et al.
  Pubblicazione: (2003)
• A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
  di: Scott, Andrew M., et al.
  Pubblicazione: (2007)
• Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
  di: Panousis, C, et al.
  Pubblicazione: (2005)
• Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization
  di: Gan, Hui K, et al.
  Pubblicazione: (2009)
• A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
  di: Jungbluth, Achim A., et al.
  Pubblicazione: (2003)